OP36 Efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately-to-severely active Ulcerative Colitis: Results through week... von Sands, B E, Feagan, B G, Sandborn, W J, Shipitofsky, N, Marko, M, Sheng, S, Johanns, J, Germinaro, M, Vetter, M, Panés, J

Volltext

P3.04-013 Phase 1 Study of the Anti-HER3 Antibody Drug Conjugate U3-1402 in Metastatic or Unresectable EGFR-Mutant NSCLC von Jänne, P., Yu, H., Vigliotti, M., Shipitofsky, N., Singh, J., Guevara, F., Yu, C.

Volltext

P3.04-012 Phase 1 Study of the AXL Inhibitor DS-1205c in Combination with Osimertinib in Subjects with Metastatic or Unresectable EGFR-Mutant NSCLC von Jänne, P., Yu, H., Vigliotti, M., Shipitofsky, N., Li, J., Mcgill, J., Yu, C.

Volltext

P493 QUASAR Induction Study 1 Cumulative Response to Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis von Peyrin-Biroulet, L, Rubin, D, Lichtenstein, G, Shipitofsky, N, Huang, K H, Germinaro, M, Wilson, R, Zhang, H, DuVall, G A, Cao, Q, Allegretti, J, Feagan, B, Hisamatsu, T, Panés, J, Dignass, A, Bressler, B, Sands, B

Volltext

P2.13-08 Phase 1 Study of the AXL Inhibitor DS-1205c in Combination with Osimertinib in Subjects with Metastatic or Unresectable EGFR-Mutant NSCLC von Jänne, P., Yu, H., Shipitofsky, N., Vigliotti, M., Goldberg, T., Li, J., Mcgill, J., Zhang, H., Yu, C.

Volltext

P2.13-43 Phase 1 Study of the Anti-HER3 Antibody Drug Conjugate U3-1402 in Metastatic or Unresectable EGFR-Mutant NSCLC von Jänne, P., Yu, H., Johnson, M., Steuer, C., Vigliotti, M., Shipitofsky, N., Guevara, F.M., Chen, S., Yu, C.

Volltext

OP23 The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Ulcerative Colitis: Phase 2b QUASAR Study results through week 12 von Dignass, A, Rubin, D, Bressler, B, Huang, K H, Shipitofsky, N, Germinaro, M, Zhang, H, Johanns, J, Feagan, B, Sandborn, W, Sands, B, Hisamatsu, T, Lichtenstein, G, Panes, J, Allegretti, J

Volltext